Pfizer to buy Baxter's marketed vaccines portfolio for $635 mn

Pfizer Inc has entered into a definitive agreement to acquire Baxter International Inc’s portfolio of marketed vaccines for $635 million. As part of the transaction, Pfizer will also acquire a portion of Baxter’s facility in Orth, Austria, where these vaccines are manufactured. 
 
Baxter’s portfolio of marketed vaccines consists of NeisVac-C and FSME-IMMUN/TicoVac.  NeisVac-C is a vaccine that helps protect against meningitis caused by group C meningococcal meningitis (MenC), which is one of the most prevalent meningococcal serogroups in many parts of the world.
 
FSME-IMMUN/TicoVac is a vaccine that helps protect against tick-borne encephalitis (TBE), an infection of the brain, which is transmitted by the bite of ticks infected with the TBE-virus. FSME-IMMUN/TicoVac is approved in 30 countries and has been marketed for over 30 years with approximately 120 million doses produced since 1976.
 
Susan Silbermann, Vaccines President, Pfizer, said, “For over a decade Pfizer has been the global leader in pneumococcal disease prevention. We are working hard to bring innovative vaccines to market that prevent and treat serious diseases. Through this acquisition, we will add two high-quality and life-saving vaccines that bring scale and depth to our portfolio.”